


## SB357134

Cat. No.:	HY-119061
CAS No.:	219963-52-7
Molecular Formula:	C <sub>17</sub> H <sub>18</sub> Br <sub>2</sub> FN <sub>3</sub> O <sub>3</sub> S
Molecular Weight:	523.21
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	SB-357134 is a potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist. SB-357134 enhances memory and learning and increases seizure threshold in rats <sup>[1]</sup> .														
<b>In Vitro</b>	SB-357134 (0.1, 0.3, 1, and 3 μM) concentration-dependently inhibits the 5-HT-mediated increased level of cAMP, which is surmountable at high 5-HT concentrations, consistent with competitive antagonism <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.														
<b>In Vivo</b>	<p>SB-357134 dose-dependently inhibits the specific [<sup>125</sup>I]SB-258585 binding<sup>[1]</sup>.</p> <p>SB-357134 (0.03-30 mg/kg; 0-24 h; p.o.; single dose) produces a potent and dose-related anticonvulsant effect in the MEST model, with a minimum significantly effective dose of 0.1 mg/kg<sup>[1]</sup>.</p> <p>Chronic administration of SB-357134 (10 mg/kg; p.o.; twice daily; 7 days) significantly shortens path length compared to vehicle and acute administration of SB-357134<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Sprague-Dawley rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.03–30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>0-24 h; p.o.; 0.03–30 mg/kg</td> </tr> <tr> <td>Result:</td> <td>Produced a potent and dose-related anticonvulsant effect in the rat MEST model, with a minimum significantly effective dose of 0.1 mg/kg. Increased seizure threshold up to 123±12% at the highest dose tested of 30 mg/kg. At 10 mg/kg, exhibited a rapid onset of action, significantly increasing seizure threshold from a control value of 21.7 to 26.7 mA at 1 h postdose. Observed Peak activity within 4–6 h postdose. With the exception of an unexplained loss of activity at 12 h, had a long duration of action of 21 h in this model.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Sprague-Dawley rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>10 mg/kg; p.o.; twice daily; 7 days</td> </tr> </table>	Animal Model:	Sprague-Dawley rats <sup>[1]</sup>	Dosage:	0.03–30 mg/kg	Administration:	0-24 h; p.o.; 0.03–30 mg/kg	Result:	Produced a potent and dose-related anticonvulsant effect in the rat MEST model, with a minimum significantly effective dose of 0.1 mg/kg. Increased seizure threshold up to 123±12% at the highest dose tested of 30 mg/kg. At 10 mg/kg, exhibited a rapid onset of action, significantly increasing seizure threshold from a control value of 21.7 to 26.7 mA at 1 h postdose. Observed Peak activity within 4–6 h postdose. With the exception of an unexplained loss of activity at 12 h, had a long duration of action of 21 h in this model.	Animal Model:	Sprague-Dawley rats <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	10 mg/kg; p.o.; twice daily; 7 days
Animal Model:	Sprague-Dawley rats <sup>[1]</sup>														
Dosage:	0.03–30 mg/kg														
Administration:	0-24 h; p.o.; 0.03–30 mg/kg														
Result:	Produced a potent and dose-related anticonvulsant effect in the rat MEST model, with a minimum significantly effective dose of 0.1 mg/kg. Increased seizure threshold up to 123±12% at the highest dose tested of 30 mg/kg. At 10 mg/kg, exhibited a rapid onset of action, significantly increasing seizure threshold from a control value of 21.7 to 26.7 mA at 1 h postdose. Observed Peak activity within 4–6 h postdose. With the exception of an unexplained loss of activity at 12 h, had a long duration of action of 21 h in this model.														
Animal Model:	Sprague-Dawley rats <sup>[1]</sup>														
Dosage:	10 mg/kg														
Administration:	10 mg/kg; p.o.; twice daily; 7 days														

---

Result:

Significantly shortened path length when administered chronically compared to vehicle and administered acutely.

---

## REFERENCES

---

[1]. Stean TO, et al. Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist. Pharmacol Biochem Behav. 2002 Apr;71(4):645-54.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA